How a Psilocybin Study on AIDS Survivors Could Solve a Big Problem with Psychedelic Therapy
Research, Treatment
A group psilocybin study paves the way for increased scalability of novel treatments that typically require a lot of time for both the patient and therapist.
Trackbacks & Pingbacks
[…] month, Health Canada’s new Special Access Program (SAP) amendment went into effect, allowing physicians to request access to psilocybin, MDMA, DMT, LSD, and other psychedelic […]
Leave a Reply
Want to join the discussion?Feel free to contribute!